← Back to patent-cliff list
Elafibranor
Tier C — Watch / tradeElafibranor
Genfit Corp
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PPARα, PPARδ
Brand：Iqirvo
Indications (approved)：Sclerosing cholangitis, Biliary cirrhosis
Regional status
US
Approved
2024-06-10
EU
Approved
2024-09-19
China
Phase III
2026-09-14
Japan
Phase III
2025-01-16
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Elafibranor?
Approved indications include: Sclerosing cholangitis, Biliary cirrhosis.
When does the Elafibranor patent expire?
No public expiry year is available for Elafibranor yet; this page updates once verified.
How do I get a quote for Elafibranor intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27